
Cancer in elderly people accounts for more than 50% of the zzso tumors treated per year in France and this population of patients has a rather zzso zzso zzso is active in these elderly patients but clearly more toxic than for young zzso The general tendency among the physicians to zzso reduce the doses is due to the known increased risk of unexpected zzso That is why there is such a large variety of conflicting opinions in the literature concerning the benefit and toxic effects of zzso drugs in the zzso zzso it appears consistent to adjust chemotherapy regimen according to zzso zzso Among them is biological age which is a better zzso than zzso age to describe the biological zzso of this population of zzso Nakamura et al have published an interesting model for the calculation of biological age by principal component analysis using 11 easily measurable biological and clinical variables in a series of healthy elderly zzso This kind of approach is not at present available for cancer patients but it allows to demonstrate that the zzso age is only one among many other age-related variables and is not sufficient to fully describe zzso The variations in zzso data are more frequent in the elderly than in younger people and this reflects age-related zzso zzso This factor is well taken into account in recently described population zzso models, zzso fittings and zzso control which may represent promising approaches of zzso dose zzso Such models have been successfully developed in young patients receiving zzso methotrexate, zzso and zzso They require a low number of blood samples to determine individual parameters and further adjust the doses, and are therefore of potential interest in old zzso Prospective studies are warranted in the future in order to recommend their use in the zzso 

